Could the Pfizer–Hospira deal be a stepping stone to a company split?
Charlotte Barker |
In early February, Pfizer announced that it would acquire Hospira for around $17 billion. Hospira’s shareholders are set to profit from the deal, with Pfizer paying $90 per share, a 40 percent premium, and netting Hospira CEO F. Michael Ball an estimated $80 million payout (1).
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine